Divi#39;s Labs set for big margin boost but valuations expensive, says MOFSL
- Hot Stocks
admin
- 0
- 1 minute read
The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company’s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said
